Triple

T6006063
Position Surface form Disambiguated ID Type / Status
Subject ICH Q10 Pharmaceutical Quality System E133712 entity
Predicate hasAbbreviation P43 FINISHED
Object ICH Q10 E133712 NE FINISHED

How this triple was built (2 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: ICH Q10 | Statement: [ICH Q10 Pharmaceutical Quality System, hasAbbreviation, ICH Q10]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07 
Target entity: ICH Q10
Context triple: [ICH Q10 Pharmaceutical Quality System, hasAbbreviation, ICH Q10]
  • A. ICH Q10 Pharmaceutical Quality System chosen
    ICH Q10 Pharmaceutical Quality System is an international guideline that establishes a comprehensive, lifecycle-based framework for pharmaceutical quality management to ensure consistent product quality and regulatory compliance.
  • B. ICH Q9 Quality Risk Management
    ICH Q9 Quality Risk Management is an international guideline that provides a systematic, science- and risk-based approach to identifying, evaluating, and controlling quality risks throughout the lifecycle of pharmaceutical products.
  • C. ICH Q11 Development and Manufacture of Drug Substances
    ICH Q11 Development and Manufacture of Drug Substances is an ICH guideline that provides principles and expectations for the development and manufacturing of chemical and biotechnological drug substances within a quality-by-design framework.
  • D. ICH Q8 Pharmaceutical Development
    ICH Q8 Pharmaceutical Development is an international guideline that outlines a systematic, science- and risk-based approach to pharmaceutical product and process development, forming a core part of the ICH quality framework.
  • E. ICH Q3A Impurities in New Drug Substances
    ICH Q3A Impurities in New Drug Substances is an international regulatory guideline that sets quality standards and thresholds for identifying, reporting, and controlling impurities in new active pharmaceutical ingredients.
  • F. None of above.
  • G. Unsure - the case is ambiguous/there is not enough information to decide.

Provenance (3 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69c00872444c8190bfaf1739dcec765c completed March 22, 2026, 3:19 p.m.
NER Named-entity recognition batch_69c04f128354819088971ee398cbda77 completed March 22, 2026, 8:20 p.m.
NED1 Entity disambiguation (via context triple) batch_69c11365741c819097a43a49dd2428c1 completed March 23, 2026, 10:18 a.m.
Created at: March 22, 2026, 4:06 p.m.